Archive · 24 Aug 2026
Three Nippon India Funds Show Strong Long-Term SIP Returns
The article looks at what could have happened if someone invested ₹10,000 every month in three Nippon India funds for 20 years.
The Pharma Fund produced the highest illustrated value, nearly ₹2 crore.
The Growth Mid Cap Fund reached about ₹1.69 crore, while the Multi Cap Fund reached about ₹1.47 crore.
These figures come from historical returns, not a promise about the future.
The funds performed less strongly over the most recent three-year period.
The Pharma Fund mainly invests in healthcare companies, so it depends heavily on one industry.
The other two funds spread money across more types of companies but can still be volatile.
Investors should choose based on their goals and comfort with risk, not past returns alone.
Nippon India Pharma, Growth Mid Cap and Multi Cap funds posted more than 15% SIP returns over most five- to 20-year periods.
A hypothetical ₹10,000 monthly SIP maintained for 20 years grew to ₹1.96 crore, ₹1.69 crore and ₹1.47 crore, respectively.
Three-year SIP returns were weaker, ranging from 7.99% for Multi Cap to 13.68% for Pharma Fund.
All three funds carry a Very High risk rating, with the Pharma Fund especially concentrated in one sector.
The article cautions that historical performance does not guarantee future returns and says investors should assess risk, goals and time horizon.
- Who
- Nippon India Pharma Fund, Nippon India Growth Mid Cap Fund and Nippon India Multi Cap Fund, along with investors considering them.
- What
- A comparison of the funds’ historical SIP and lump-sum returns, portfolio characteristics and risks.
- When
- The comparison covers three-, five-, 10-, 15- and 20-year periods; asset figures are stated as of July 31, 2026.
- Where
- The funds invest in Indian companies across sectors, including pharma, healthcare, financials, technology and consumer businesses.
- Why
- The article examines whether strong long-term historical returns justify closer consideration while emphasizing that the funds carry Very High risk.
Long-Term Return Case
Risk and Caution Case
Historical performance
Long-Term Return Case
The funds recorded more than 15% SIP returns across the reported five-, 10-, 15- and 20-year periods, with the Pharma Fund producing the highest 20-year illustration.
Risk and Caution Case
Recent three-year SIP returns were below 15% for all three funds, showing that long-term averages can conceal weaker shorter-term periods.
Portfolio choice
Long-Term Return Case
The Growth Mid Cap and Multi Cap funds offer exposure across multiple companies and sectors, while the Pharma Fund has delivered strong historical results from healthcare exposure.
Risk and Caution Case
The Pharma Fund is a concentrated sectoral bet, and the diversified funds still carry volatility associated with mid-cap and multi-cap investing.
Investment decision
Long-Term Return Case
The historical SIP examples suggest that staying invested for a long period can build substantial wealth through market cycles.
Risk and Caution Case
Past performance is not a guarantee of future returns, and investors should consider objectives, risk appetite, portfolio concentration and time horizon before investing.
- 20-year SIP illustration
- A ₹10,000 monthly SIP was illustrated at ₹1.96 crore for Pharma Fund, ₹1.69 crore for Growth Mid Cap Fund and ₹1.47 crore for Multi Cap Fund.
- Total contribution
- The 20-year SIP illustration represents total contributions of ₹24 lakh.
- Three-year SIP returns
- Pharma Fund: 13.68%; Growth Mid Cap Fund: 13.49%; Multi Cap Fund: 7.99%.
- 20-year SIP returns
- Pharma Fund: 18.06%; Growth Mid Cap Fund: 16.91%; Multi Cap Fund: 15.80%.
- Fund assets
- As of July 31, 2026, assets were stated at ₹9,279 crore for Pharma Fund, ₹50,751 crore for Growth Mid Cap Fund and ₹55,587 crore for Multi Cap Fund.
- Risk rating
- All three funds have a Very High riskometer rating.
- Portfolio concentration
- The Pharma Fund’s top 10 holdings account for about 57% of its portfolio, compared with about 25% for the Growth Mid Cap Fund.
- Plan-label discrepancy
- The fund names are presented with “Direct Plan – Growth,” but the article later describes all three as regular plans and explains that regular plans are used for long historical comparisons.